EyePoint Pharmaceuticals (PV3B) Financial Statements
EyePoint Pharmaceuticals Financial Overview
EyePoint Pharmaceuticals's market cap is currently $26.80M. The company's EPS TTM is $-3.74; its P/E ratio is -0.09; EyePoint Pharmaceuticals is scheduled to report earnings on November 4, 2026, and the estimated EPS forecast is $-0.83. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 31.37M | $ 43.27M | $ 46.02M | $ 41.40M | $ 36.94M |
| Gross Profit | $ 29.30M | $ 39.56M | $ 41.39M | $ 33.08M | $ 28.76M |
| Operating Income | $ -243.43M | $ -145.85M | $ -75.07M | $ -99.64M | $ -55.28M |
| EBITDA | $ -229.34M | $ -129.23M | $ -69.00M | $ -96.62M | $ -50.15M |
| Net Income | $ -231.96M | $ -130.87M | $ -70.80M | $ -102.25M | $ -58.42M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 306.09M | $ 370.91M | $ 331.05M | $ 144.56M | $ 211.56M |
| Total Assets | $ 364.00M | $ 418.46M | $ 355.18M | $ 180.36M | $ 263.37M |
| Total Debt | $ 22.79M | $ 21.86M | $ 4.91M | $ 46.35M | $ 39.20M |
| Net Debt | $ -79.03M | $ -77.85M | $ -276.36M | $ -49.28M | $ -139.39M |
| Total Liabilities | $ 57.88M | $ 81.96M | $ 88.86M | $ 83.99M | $ 78.99M |
| Stockholders' Equity | $ 306.11M | $ 336.50M | $ 266.32M | $ 96.37M | $ 184.38M |
| Cash Flow | |||||
| Free Cash Flow | $ -243.39M | $ -130.28M | $ -1.61M | $ -67.16M | $ -50.25M |
| Operating Cash Flow | $ -240.11M | $ -126.23M | $ 1.88M | $ -65.00M | $ -50.10M |
| Investing Cash Flow | $ 68.58M | $ -219.35M | $ -3.31M | $ -17.27M | $ -33.12M |
| Financing Cash Flow | $ 173.65M | $ 164.02M | $ 187.07M | $ -690.00K | $ 216.90M |
Currency in USD